Terms ending in 2028
Every in-force patent on AbbVie Inc.'s record whose computed term ends in 2028, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 7,547,678 | Method for Treating a Disease, Disorder or Adverse Effect Caused by an Elevated Serum Concentration of an Ugtiai Substrate In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 7,750,004 | Apoptosis Promoters In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 7,576,110 | Benzothiazole Cyclobutyl Amine Derivatives In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 7,790,741 | Novel Imidazothiazoles and Imidazoxazoles In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 8,183,250 | Potent Parp Inhibitors In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 9,592,293 | INTERLEUKIN-13 Binding Proteins In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 8,410,259 | Recombinant Expression Vector Elements (REVES) for Enhancing Expression of Recombinant Proteins in Host Cells In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 9,035,047 | 7-Substituted Indole MCL-1 Inhibitors In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 9,359,296 | 7-Substituted Indole MCL-1 Inhibitors In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 8,546,368 | Pyrazoloquinolones Are Potent Parp Inhibitors In force · High confidence | AbbVie Inc. | In force | High confidence | |
| 20 more term ends in 2028 · Pro | |||||
10 of 30 patents shown. Soonest term end first, then patent number.
Pro members see all 30, including 9 expiring within the 18 months from Nov 21, 2026.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.